Table 1.
Baseline characteristics of patients from study [ClinicalTrials.gov identifier: NCT01766817].
| Parameter | BMS-986020 600 mg QD (n = 46) | BMS-986020 600 mg BID (n = 46) | Placebo (n = 45) | Total (N = 137) |
|---|---|---|---|---|
| Age, mean (SD), years | 68.52 (6.65) | 69.17 (8.36) | 69.33 (7.56) | 69.00 (7.55) |
| Sex, male, n (%) | 32 (70) | 34 (74) | 33 (73) | 99 (72) |
| Predicted FVC, mean (SD), % | 69.95 (12.28) | 68.59 (12.32) | 69.22 (11.27) | 69.25 (11.89) |
| Predicted DLCO, mean (SD), % | 45.69 (16.92) | 40.23 (12.62) | 44.33 (12.77) | 43.41 (14.34) |
| UCSD-SOBQ score, mean (SD) | 45.76 (23.51) | 42.52 (23.64) | 37.42 (23.35) | 41.93 (23.58) |
| QLF whole lung, mean (SD), % | 19.00 (9.71) | 17.90 (8.03) | 17.36 (7.08) | 18.09 (8.32) |
| QILD whole lung, mean (SD), % | 40.54 (13.19) | 37.82 (11.55) | 37.07 (10.24) | 38.48 (11.74) |
| QLF whole lung, mean (SD), mla | 703.18 (393.36) | 623.93 (246.91) | 622.91 (262.79) | 650.21 (308.45) |
| QILD whole lung, mean (SD), mlb | 1,491.37 (560.44) | 1,349.32 (439.83) | 1,348.52 (455.14) | 1,396.75 (489.40) |
a
QLF (ml) was derived from the product of CT TLC volume and QLF (%).
b
QILD (mL) was derived from the product of CT TLC volume and QILD (%).
BID, twice daily; DLCO, diffusing capacity of the lungs for carbon monoxide; FVC, forced vital capacity; QD, once daily; QILD, quantitative interstitial lung disease; QLF, quantitative lung fibrosis; SD, standard deviation; TLC, total lung capacity; UCSD-SOBQ, University of California San Diego Shortness of Breath Questionnaire.